

1	MPNFFIDRPI	FAWVIAIIIM	LAGGLAILKL	PVAQYPTIAP	PAVTISASYP
51	GADAKTVQDT	VTQVIEQNMN	GIDNLMYMSS	NSDSTGTVQI	TLTFESGTDA
101	DIAQVQVQNK	LQLAMPLLPQ	EVQQQGVSVE	KSSSSFLMVV	GVINTDGTMT
151	QEDISDYVAA	NMKDAISRTS	GVGDVQLFGS	QYAMRIWMNP	NELNKFQLTP
201	VDVITAIKAQ	NAQVAAGQLG	GTPPVKGQQL	NASIIAQTRL	TSTEEFGKIL
251	LKVNQDGSRV	LLRDVAKIEL	GGENYDIIAE	FNGQPASGLG	IKLATGANAL
301	DTAAAIRAEL	AKMEPFFPSG	LKIVYPYDTT	PFVKISIHEV	VKTLVEAIIL
351	VFLVMYLFLQ	NFRATLIPTI	AVPVVLLGTF	AVLAAFGFSI	NTLTMFGMVL
401	AIGLLVDDAI	VVVENVERVM	AEEGLPPKEA	TRKSMGQIQG	ALVGIAMVLS
451	AVFVPMAFFG	GSTGAIYRQF	SITIVSAMAL	SVLVALILTP	ALCATMLKPI
501	AKGDHGEGKK	GFFGWFNRMF	EKSTHHYTDS	VGGILRSTGR	YLVLYLIIVV
551	GMAYLFVRLP	SSFLPDEDQG	VFMTMVQLPA	GATQERTQKV	LNEVTHYYLT
601	KEKNNVESVF	AVNGFGFAGR	GQNTGIAFVS	LKDWADRPGE	ENKVEAITMR
651	ATRAFSQIKD	AMVFAFNLPA	IVELGTATGF	DFELIDQAGL	GHEKLTQARN
701	QLLAEAAKHP	DMLTSVRPNG	LEDTPQFKID	IDQEK AQALG	VSINDINTTL
751	GAAWGGSYVN	DFIDRGRVK <mark>K</mark>	VYVMSEAKYR	MLPDDIGDWY	VRAADGQMVP
801	FSAFSSSRWE	YGSPRLERYN	GLPSMEILGQ	AAPGKSTGEA	MELMEQLASK
851	LPTGVGYDWT	GMSYQERLSG	NQAPSLYAIS	LIVVFLCLAA	LYESWSIPFS
901	VMLVVPLGVI	GALLAATFRG	LTNDVYFQVG	LLTTIGLSAK	NAILIVEFAK
951	DLMDKEGKGL	IEATLDAVRM	RLRPILMTSL	AFILGVMPLV	ISTGAGSGAQ
1001	NAVGTGVMGG	MVTATVLAIF	FVPVFFVVVR	RRFSRKNEDI	EHSHTVDHH

Figure 1. Identification of the purified AcrB protein. (A) SDS-PAGE. M: protein molecular weight marker; FT: flow through; W1: wash by 30 mM imidazole; W2: wash by 50mM imidazole; E: elution by 500 mM imidazole. The black arrow indicated overexpressed AcrB. **(B) AcrB sequence coverage determined by MS.** Taxonomy: *E. coli* K-12. Sequence coverage: 41%. Identified peptides were shown in red.

(B)

Drug group and drug	IC50 (µg/mL)		Relative resistance				
	Kam3	Kam3-AcrB					
Macrolide							
Erythromycin	7.812	250	32				
Clarithromycin	10.937	87.5	8				
Quinolone							
Norfloxacin	0.78	1.56	2				
Tetracycline							
Tetracycline	0.098	0.39	4				
Rifampicin	0.625	1.25	2				
Dyes							
Hoechst 33342	7.812	15.625	2				
Ethidium bromide	25	100	4				
Nile red	>16	>16	1				

Table S1. The IC_{50} of Kam3, and Kam3-AcrB against dyes and drugs.



Increased substrates in the extracellular space monitored by using MALDI-TOF.

Fewer substrates in the extracellular space as compared with the no EPI group.



Figure S2. The influx and efflux of the substrates when they are incubated with the *E. coli* cells.



Figure S3. The calibration curves of dyes (A) Hoechst 33342 (B) EtBr (C) Nile red. Values were expressed as mean \pm standard deviation (SD) (n = 3).

(A)

(A)



Figure S4. The calibration curves of dyes (**A**) Erythromycin (**B**) Rifampicin. Values were expressed as mean \pm standard deviation (SD) (n = 3).